InvestSMART

Epsilon Healthcare Limited (ASX:EPN)

ALERT: Price-sensitive ASX Announcement for EPN
Current share price for EPN : $0.022 -0.008 (-26.67%)+
Announcement
Release
5 Feb 2026 11:11AM
Price at Release
$0.030
Full Release
download
Summary
Epsilon Healthcare Limited, through its subsidiary Epsilon Pharma Pty Ltd, has formed a manufacturing agreement with Puro New Zealand Limited. This partnership is aimed at producing GMP-certified finished formulation products for export, initially to the UK in Q1 2026, with plans for further expansion into Europe. The agreement is designed to leverage Epsilon's EU GMP certifications, manufacturing capabilities, and international licensure. It represents a strategic move to capture growth opportunities in the European healthcare and pharmaceuticals markets, emphasizing Epsilon's commitment to building a global portfolio and delivering high-quality pharmaceutical solutions. The partnership is expected to generate AU $6 million over three years and aligns with Epsilon's strategy of building long-term, mutually beneficial partnerships.
Key Points
  • Epsilon Pharma signs a manufacturing agreement with Puro NZ.
  • Initial focus on exporting to the UK, expanding to Europe.
  • Epsilon to leverage EU GMP certifications and manufacturing capabilities.
  • Expected revenue of AU $6 million over three years.
  • Partnership enhances Epsilon's global competitive position in healthcare.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.